ES2139077T3 - Medicamento contra el estres, la degeneracion y el envejecimiento y proceso para su fabricacion. - Google Patents
Medicamento contra el estres, la degeneracion y el envejecimiento y proceso para su fabricacion.Info
- Publication number
- ES2139077T3 ES2139077T3 ES94919023T ES94919023T ES2139077T3 ES 2139077 T3 ES2139077 T3 ES 2139077T3 ES 94919023 T ES94919023 T ES 94919023T ES 94919023 T ES94919023 T ES 94919023T ES 2139077 T3 ES2139077 T3 ES 2139077T3
- Authority
- ES
- Spain
- Prior art keywords
- stress
- drug
- enterosoluble
- vitamin
- aging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940079593 drug Drugs 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000032683 aging Effects 0.000 title 1
- 230000007850 degeneration Effects 0.000 title 1
- 230000035882 stress Effects 0.000 title 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 229930091371 Fructose Natural products 0.000 abstract 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract 1
- 239000005715 Fructose Substances 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- QKHNQACCGKTTKA-UHFFFAOYSA-N O(C1=CC=CC=C1)CC(=O)OC(C)N Chemical class O(C1=CC=CC=C1)CC(=O)OC(C)N QKHNQACCGKTTKA-UHFFFAOYSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 229930003451 Vitamin B1 Natural products 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 150000003869 acetamides Chemical class 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000001195 anabolic effect Effects 0.000 abstract 1
- 230000003712 anti-aging effect Effects 0.000 abstract 1
- 230000002180 anti-stress Effects 0.000 abstract 1
- 230000001147 anti-toxic effect Effects 0.000 abstract 1
- 229940009098 aspartate Drugs 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 150000007942 carboxylates Chemical class 0.000 abstract 1
- 230000001925 catabolic effect Effects 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000003284 homeostatic effect Effects 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 229910052744 lithium Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- QMEYHMGPFYXWNU-UHFFFAOYSA-N n-(2-aminoethyl)-2-phenoxyacetamide Chemical class NCCNC(=O)COC1=CC=CC=C1 QMEYHMGPFYXWNU-UHFFFAOYSA-N 0.000 abstract 1
- 230000000444 normolipidemic effect Effects 0.000 abstract 1
- 230000001590 oxidative effect Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 229960003495 thiamine Drugs 0.000 abstract 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract 1
- 230000000304 vasodilatating effect Effects 0.000 abstract 1
- 229940124549 vasodilator Drugs 0.000 abstract 1
- 239000003071 vasodilator agent Substances 0.000 abstract 1
- 235000010374 vitamin B1 Nutrition 0.000 abstract 1
- 239000011691 vitamin B1 Substances 0.000 abstract 1
- 235000019158 vitamin B6 Nutrition 0.000 abstract 1
- 239000011726 vitamin B6 Substances 0.000 abstract 1
- 229940011671 vitamin b6 Drugs 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
LA INVENCION SE REFIERE A UNA NUEVA ESTRATEGIA FARMACOTERAPEUTICA, A UN FARMACO ANTIESTRES, ANTIDETERIORO Y ANTIENVEJECIMIENTO Y A UN PROCESO PARA SU FABRICACION. EL FARMACO TIENE UNA ACCION ETIOPATOGENICA Y HOMEOSTATICA, SE ENSAYO PRECLINICAMENTE Y VERIFICO CLINICAMENTE EN PATOLOGIAS GERIATRICAS, NEUROLOGICAS, PSIQUIATRICAS Y DEPENDIENTES DEL ESTRES. CON EL FARMACO SE CONSIGUE UNA COMPOSICION BIOLOGICA, NEUROMETABOLICA Y CELULOTROFICA, ELABORADA MEDIANTE LA ASOCIACION DE LOS SIGUIENTES PRINCIPIOS ACTIVOS: A) CONTRA EL ESTRES OXIDATIVO Y CATABOLICO: METIONINA CON AMINOETANOLFENOXIACETATOS Y/O AMINOETILFENOXIACETAMIDAS; B) CONTRA EL ESTRES ANABOLICO: CARBOXILATOS DE HIDROOXOPIRIMIDINA Y/O ACETAMIDAS DE OXOPIRROLIDINA CON POTASIO, ZINC Y LITIO; C) VASODILATADORA Y NORMOLIPIDEMICA: ALCOHOL Y/O ACIDO NICOTINICO, O SUS DERIVADOS, CON MAGNESIO Y YODO; D) ENERGOACTIVA Y E) ANTITOXICA: ASPARTATO; FRUCTOSA; VITAMINA B{SUB,1}; VITAMINA B{SUB,6}; FOSTATO Y SULFATO MONOACIDOS. EL PROCESO PARA LA FABRICACION DEL FARMACO ESTIPULA: A) PREPARACION FARMACEUTICA DE DOS TIPOS COMPLEMENTARIOS DE CAPSULAS O COMPRIMIDOS REVESTIDOS, GASTROSOLUBLES Y ENTEROSOLUBLES, DONDE LOS ULTIMOS TIENEN UN REVESTIMIENTO ENTERICO; B) LIBERACION PROLONGADA DEL VASODILATADOR DE LA UNIDAD ENTEROSOLUBLE.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR9408581A BR9408581A (pt) | 1994-06-02 | 1994-06-02 | Medicamento anti-tens o anti-incapacitação e anti-envelhecimento e processo para a sua produção |
| PCT/RO1994/000003 WO1995033486A1 (en) | 1994-06-02 | 1994-06-02 | Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2139077T3 true ES2139077T3 (es) | 2000-02-01 |
Family
ID=25664670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES94919023T Expired - Lifetime ES2139077T3 (es) | 1994-06-02 | 1994-06-02 | Medicamento contra el estres, la degeneracion y el envejecimiento y proceso para su fabricacion. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6174890B1 (es) |
| EP (1) | EP0804239B1 (es) |
| JP (1) | JP3455544B2 (es) |
| AT (1) | ATE184490T1 (es) |
| AU (1) | AU694125B2 (es) |
| BR (1) | BR9408581A (es) |
| CA (1) | CA2191837C (es) |
| DE (1) | DE69420746T2 (es) |
| DK (1) | DK0804239T3 (es) |
| ES (1) | ES2139077T3 (es) |
| WO (1) | WO1995033486A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703127A (en) * | 1996-01-25 | 1997-12-30 | Pak; Kyoungsik | Composition, dosage unit, and method for treating stomach disorders |
| GB2312621B (en) * | 1996-05-02 | 1998-03-11 | Pharma Nord Uk Limited | Anti-oxidant medicament |
| WO2000032179A2 (en) * | 1998-12-01 | 2000-06-08 | University Of Kentucky Research Foundation | Use of nicotonic acid derivatives for the treatment of dna damage in skin cells |
| US6726939B1 (en) | 2000-03-22 | 2004-04-27 | Kyoungsik Pak | Composition and method for reducing blood pressure, alleviating or eliminating angina pectoris and headaches, and enhancing skin and hair |
| DE10018834A1 (de) * | 2000-04-15 | 2001-10-25 | Lohmann Therapie Syst Lts | Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung |
| EA005383B1 (ru) * | 2001-12-28 | 2005-02-24 | Федеральное Государственное Унитарное Предприятие "Центр Экстремальной Медицины" | Способ фармакологической коррекции работоспособности человека в экстремальных ситуациях |
| US20040001817A1 (en) * | 2002-05-14 | 2004-01-01 | Giampapa Vincent C. | Anti-aging nutritional supplement |
| JPWO2004026296A1 (ja) * | 2002-09-18 | 2006-01-12 | 味の素株式会社 | 抗ストレス性疾患組成物 |
| ITRN20030021A1 (it) * | 2003-07-21 | 2005-01-22 | Ascor Chimici Srl | Composizione di materia comprendente particelle contenenti cloruro di colina da somministrare in forma ruminalmente protetta e post-ruminalmente efficace. |
| US20050214388A1 (en) * | 2004-02-18 | 2005-09-29 | Gorham Thomas R | Multivitamin formulations containing controlled-release magnesium |
| CN101027061B (zh) | 2004-05-11 | 2014-03-12 | 情感智能有限责任公司 | 药物制剂及其在治疗女性性功能障碍中的应用 |
| ITMI20041820A1 (it) * | 2004-09-24 | 2004-12-24 | Ascor Chimici Srl | Composizione in micro-pellets a rilascio controllato di sostanze fisiologicamente attive, procedimento di preparazione e relativo impiego nel settore zootecnico. |
| US20060153900A1 (en) * | 2005-01-13 | 2006-07-13 | Pins Joel J | Dietary supplement for treatment of lipid risk factors |
| US20060252831A1 (en) * | 2005-05-06 | 2006-11-09 | Christopher Offen | Method for the treatment of magnesium and potassium deficiencies |
| US20060252830A1 (en) * | 2005-05-06 | 2006-11-09 | Brandon Stephen F | Method for the treatment of magnesium and potassium deficiencies |
| US8263137B2 (en) * | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| US7998500B2 (en) * | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| US7901710B2 (en) * | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| US8202546B2 (en) * | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| WO2007073006A1 (ja) * | 2005-12-22 | 2007-06-28 | Keio University | 細胞保護性を有するアミノ酸の増加誘導剤及び増加方法 |
| RU2330659C1 (ru) * | 2006-10-23 | 2008-08-10 | ФГУ Российский научно-исследовательский нейрохирургический институт им. проф. А.Л. Поленова | Способ лечения диэнцефально-катаболического синдрома |
| EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| JP2008174512A (ja) * | 2007-01-22 | 2008-07-31 | Kracie Seiyaku Kk | 起床時疲労感改善用組成物 |
| JP5788715B2 (ja) * | 2011-05-31 | 2015-10-07 | キリンホールディングス株式会社 | 酸素消費量及びエネルギー消費量の低減剤 |
| BR112018071363A2 (pt) | 2016-04-19 | 2019-02-05 | Ferring Bv | composições farmacêuticas orais de nicotinamida |
| WO2019161331A1 (en) * | 2018-02-19 | 2019-08-22 | Marshall Timothy M | Magnesium/lithium preparations for neuroprotection and neurotrophic benefits |
| JP7874258B2 (ja) * | 2020-03-31 | 2026-06-16 | 株式会社古川リサーチオフィス | 亜鉛化合物配合組成物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3493659A (en) | 1967-10-23 | 1970-02-03 | Hoffmann La Roche | Compositions and process for the production thereof |
-
1994
- 1994-06-02 BR BR9408581A patent/BR9408581A/pt not_active Application Discontinuation
- 1994-06-02 AU AU70104/94A patent/AU694125B2/en not_active Ceased
- 1994-06-02 EP EP94919023A patent/EP0804239B1/en not_active Expired - Lifetime
- 1994-06-02 AT AT94919023T patent/ATE184490T1/de active
- 1994-06-02 DE DE69420746T patent/DE69420746T2/de not_active Expired - Lifetime
- 1994-06-02 DK DK94919023T patent/DK0804239T3/da active
- 1994-06-02 JP JP50071396A patent/JP3455544B2/ja not_active Expired - Fee Related
- 1994-06-02 CA CA002191837A patent/CA2191837C/en not_active Expired - Lifetime
- 1994-06-02 US US08/750,159 patent/US6174890B1/en not_active Expired - Lifetime
- 1994-06-02 ES ES94919023T patent/ES2139077T3/es not_active Expired - Lifetime
- 1994-06-02 WO PCT/RO1994/000003 patent/WO1995033486A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE69420746T2 (de) | 2000-06-29 |
| BR9408581A (pt) | 1997-08-26 |
| ATE184490T1 (de) | 1999-10-15 |
| DE69420746D1 (de) | 1999-10-21 |
| WO1995033486A1 (en) | 1995-12-14 |
| CA2191837A1 (en) | 1995-12-14 |
| AU7010494A (en) | 1996-01-04 |
| EP0804239A1 (en) | 1997-11-05 |
| AU694125B2 (en) | 1998-07-16 |
| JP3455544B2 (ja) | 2003-10-14 |
| US6174890B1 (en) | 2001-01-16 |
| JPH10500137A (ja) | 1998-01-06 |
| CA2191837C (en) | 2002-10-15 |
| EP0804239B1 (en) | 1999-09-15 |
| DK0804239T3 (da) | 2000-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9408581A (pt) | Medicamento anti-tens o anti-incapacitação e anti-envelhecimento e processo para a sua produção | |
| AU2008216234B2 (en) | Improved stability in vitamin and mineral supplements | |
| US7241456B2 (en) | Formulations for topical delivery of bioactive substances and methods for their use | |
| JP2023145496A (ja) | 神経細胞損傷の治療のためのアミノ酸組成物 | |
| US20100285158A1 (en) | Effervescent composition including cranberry extract | |
| CO6150127A2 (es) | Formulaciones de flibanserina y metodo para fabricarlas | |
| US20110064712A1 (en) | Dietary Supplement Compositions and Methods of Making and Using the Same | |
| WO2010032140A3 (en) | Pharmaceutical compositions and related methods of delivery | |
| US20060281822A1 (en) | Treatment and prevention of elevated homocysteine | |
| CN103751057A (zh) | 一种美白保湿抗皱面膜液及其制备方法 | |
| ES8307491A1 (es) | Un metodo para preparar una composicion de gel acuoso semi- solido para alimentacion de heridos | |
| IT1270239B (it) | Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo | |
| CN109430833A (zh) | 一种用于提高生殖细胞活力的组合物及其应用 | |
| FR3042411B1 (fr) | Composition comprenant un melange de molecules particulieres et utilisation pour agir sur le metabolisme glucidique et/ou lipidique | |
| EP1735001A2 (en) | Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs | |
| ATE329589T1 (de) | Multipartikuläre bisoprolol formulierung | |
| EP3461479A1 (en) | Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions | |
| RU2726978C2 (ru) | Сочетание липоевой кислоты и таурина в качестве осмопротекторного агента | |
| EP3215222A1 (en) | Methods of treating huntington's disease using cysteamine compositions | |
| JPS56110679A (en) | 55aminootetrazole derivative of retinoic acid* its manufacture and medicine containing it | |
| PT2838529E (pt) | Composição que compreende ácido alfa-lipóico e honokiol para tratar neuropatias | |
| WO2023037375A1 (en) | A self-emulsifying drug delivery system (sedds) of punicic acid combined with neuroprotective natural products to delay onset, prevent, or reverse neurodegenerative disease | |
| FR2556964A1 (fr) | Nouvelles formes galeniques du sulpiride utilisables par voie orale | |
| US20250073214A1 (en) | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder | |
| JP2017039687A (ja) | ナルフラフィン塩酸塩含有カプセル製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 804239 Country of ref document: ES |